EGFR and small cell lung carcinoma: Lung adenocarcinoma (LUAD) patients receiving epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapies undergo SCLC neuroendocrine transformation with RB1/TP53 mutations as well as enhancement of the PRC2 complex and PI3K/AKT pathways [5].